nference and Mayo Clinic Study Confirms Efficacy of Ad26.COV2.S Vaccine in Reducing COVID-19 Infections

CAMBRIDGE, Mass., November 2, 2021 –– nference, the AI-driven health technology company, today announced publication of a study in JAMA Network Open that analyzed Mayo Clinic data with nference augmented intelligence (AI) software to determine that the Ad26.COV2.S vaccine was over 73 percent effective at reducing the spread of SARS-CoV-2 during the study period (February to July, 2021).

Authors of “Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19” conducted a preliminary assessment of the effectiveness of the Ad26.COV2.S vaccine based on the electronic health record (EHR) data of 8,889 vaccinated patients and 88,898 unvaccinated patients. The data was captured by the Mayo Clinic between February 27 and July 22, 2021 and was used to establish a retrospective baseline for the vaccine’s efficacy. The results show that the Ad26.COV2.S vaccine’s overall effectiveness was 73.6 percent and that the Ad26.COV2.S facilitated a 3.73-fold reduction in SARS-CoV-2 infections during this time period.

JAMA Network Open is an open access medical journal published by the American Medical Association and covering all aspects of the biomedical sciences.

“As COVID-19 vaccinations continue to be administered more broadly, it has become critical for researchers and scientists to continuously assess the safety and effectiveness data for each of the vaccines,” said Tyler Wagner, PhD, vice president of biomedical research at nference. “Using nference’s state-of-the-art AI technology, we were able to quickly and accurately process and analyze the data collected by our partners at the Mayo Clinic, and these findings conclude that the Ad26.COV2.S vaccine was effective against the spread of SARS-CoV-2 during the study period.”

In the process of conducting this study, nference employed its leading-edge augmented intelligence software, nferX™, which uses proprietary natural language processing technology to rapidly synthesize vast amounts of biomedical data from disparate sources in previously incompatible formats. nference’s real-time software will continue to monitor and enable rapid up-to-date safety assessments of vaccines as new and updated patient information becomes available. A follow-on study examining the durability of the Ad26.COV2.S vaccine with the Delta variant will be forthcoming.

This innovative, powerful augmented intelligence technology implemented by nference during the COVID-19 pandemic has enabled several significant discoveries with a wide range of implications that contribute to a greater understanding of the virus, which are ultimately advancing patient care.

About nference

Through its powerful augmented intelligence software nferX®, nference is transforming health care by making biomedical knowledge computable. Its partnership with Mayo Clinic has given nference an opportunity to synthesize more than 100 years of institutional knowledge, producing real-world evidence in real time by converting large amounts of data into deep insights to advance discovery and development of diagnostics and therapeutics. nference is headquartered in Cambridge, Massachusetts. Follow nference on LinkedIn and Twitter. Visit us at nference.ai.